Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry

American Journal of Clinical Pathology

Volumn 115, Issue 4, 2001, Pages 504-511

  O'Malley, Frances P ^a,b   Parkes, Robert ^c   Latta, Eleanor ^a,b   Tjan, Suzanna ^a   Zadro, Tanya ^d   Mueller, Rosemary ^d   Arneson, Nona ^d   Blackstein, Martin ^a   Andrulis, Irene ^a,b,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Breast cancer; C erbB 2; HER2 neu; Immunohistochemistry; Predictive factor; Prognostic factor

Indexed keywords

HERCEPTEST; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CB11; MONOCLONAL ANTIBODY TAB250; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DNA DETERMINATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; BIOPSY; BREAST NEOPLASMS; CANADA; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY;

EID: 0035064429     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/VP4W-5C55-7M09-6TX3     Document Type: Article

References (45)

1. Shih C, Padhy LC, Murray M, et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature. 1981;290:261-264.
2. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312:513-516.
3. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132-1139.
4. Semba K, Kamata N, Toyoshima K, et al. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A. 1985;82:6497-6501.
5. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
6. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
7. Thor AD, Schwartz LH, Koerner FC, et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res. 1989;49:7147-7152.
8. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989;49:2087-2090.
9. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4332-4337.
10. O'Reilly SM, Barnes DM, Camplejohn RS, et al. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer. 1991;63:444-446.
11. McCann AH, Dervan PA, O'Regan M, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res. 1991;51:3296-3303.
12. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991;49:650-655.
13. Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;49:44-49.
14. Gusterson BA, Gelber RD, Goldhirsch A, et al, for the International (Ludwig) Breast Cancer Study Group. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.
15. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer. 1994;73:2359-2365.
16. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-2904.
17. Andrulis IL, Bull SB, Blackstein ME, et al, for the Toronto Breast Cancer Study Group. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol. 1998;16:1340-1349.
18. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200-206.
19. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
20. O'Malley FP, Saad Z, Kerkvliet N, et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Hum Pathol. 1996;27:955-963.
21. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998;79:502-508.
22. Neubauer A, Neubauer B, He M, et al. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene. 1992;7:1019-1025.
23. Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology: The Essentials. Baltimore, MD: Williams & Wilkins; 1996.
24. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathobgy. 1991;19:403-410.
25. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991;51:944-948.
26. Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer [published correction appears in Br J Cancer. 1991;64:202]. Br J Cancer. 1991;63:439-443.
27. Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51:556-567.
28. Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis. Cancer. 1995;75:1320-1326.
29. Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992;10:1044-1048.
30. Albanell J, Bellmunt J, Molina R, et al. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res. 1996;16:1027-1032.
31. Dykins R, Corbett IP, Henry JA, et al. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol. 1991;163:105-110.
32. Giai M, Roagna R, Ponzone R, et al. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res. 1994;14:1441-1450.
33. Marks JR, Humphrey PA, Wu K, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994;219:332-341.
34. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53:4960-4970.
35. Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat. 1995;35:283-291.
36. Seshadri R, Firgaira FA, Horsfall DJ, et al, for the South Australian Breast Cancer Study Group. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol. 1993;11:1936-1942.
37. Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991;63:447-450.
38. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599-605.
39. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.
40. Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 1994;173:65-75.
41. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361-1370.
42. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.
43. ™ (humanized anti-HER 2 antibody) as a single agent in 222 women with HER 2 overexpression who relapsed following chemotherapy for metastatic breast cancer (HER 2+/mbc) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. In: Proceedings of the American Society of Clinical Oncology. Hagerstown, MD: Lippincott; 1998. Abstract 377.
44. Herceptin (trastuzumab) [package insert]. San Francisco, CA: Genentech; 1998.
45. Jacobs TW, Gown A, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987.